Docality.com Logo
 
Dr. Naseer  Ahmad  Md image

Dr. Naseer Ahmad Md

14120 Ne 183Rd St Unit 333
Woodinville WA 98072
425 900-0695
Medical School: Other - 1979
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: MD00036229
NPI: 1295804250
Taxonomy Codes:
174400000X 207RX0202X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Naseer Ahmad is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99223 Description:Initial hospital care Average Price:$368.09 Average Price Allowed
By Medicare:
$186.53
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$183.00 Average Price Allowed
By Medicare:
$95.49
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$180.00 Average Price Allowed
By Medicare:
$96.69
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$126.78 Average Price Allowed
By Medicare:
$66.60
HCPCS Code:99205 Description:Office/outpatient visit new Average Price:$199.24 Average Price Allowed
By Medicare:
$154.22
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$130.00 Average Price Allowed
By Medicare:
$102.08
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$92.42 Average Price Allowed
By Medicare:
$72.58
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$54.00 Average Price Allowed
By Medicare:
$47.23

HCPCS Code Definitions

99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99205
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1982648820
Hematology/Oncology
2,471
1396776027
Medical Oncology
2,369
1114917960
Hematology/Oncology
1,613
1790730174
Hematology/Oncology
1,188
1548295819
Diagnostic Radiology
590
1972676476
Hematology/Oncology
430
1487677605
Diagnostic Radiology
344
1760590483
Diagnostic Radiology
324
1568495794
Diagnostic Radiology
315
1902877111
Cardiac Electrophysiology
271
*These referrals represent the top 10 that Dr. Ahmad has made to other doctors

Publications

Growth performance and meat quality of rabbits under different feeding regimes. - Tropical animal health and production
This study evaluated the growth, carcass characteristics and meat quality of indigenous rabbits in northern Pakistan. Weaned rabbits (age 35 days, weight 323 g) of four distinct phenotypes (white, black and white, brown and black) were fed four experimental diets: alfalfa hay (AH), berseem fodder (BF), BF supplemented with low-level concentrate (50 %; LLC) and high-level concentrate (75 %; HLC). Each experimental diet was fed to 48 rabbits, 12 of each phenotype, in a randomized complete block design. The duration of the experiment was 55 days, including 1 week of adaptation. Rabbits fed the BF and AH diets had poor body weight gain (P < 0.05) compared to rabbits fed the LLC and HLC diets. Feed conversion efficiency was best in the LLC (4.47) and HLC (4.58) groups. Average carcass yield (743 g) and carcass dressing percentage (56.2) were higher (P < 0.05) in LLC. Growth rate was not improved significantly by feeding HLC. Fat deposition in animals was higher (P < 0.05) in the groups supplemented with concentrate. Cost per kilogram of rabbit meat was lowest (P < 0.05) for BF, followed by AH, LLC and HLC. Brown phenotypes had the best (P < 0.05) feed conversion efficiency, body weight gain, carcass yield and carcass dressing. It was concluded that local rabbits do not necessarily need high levels of concentrates but can be well fattened with low-level concentrates along with forages.
The prevalence of major lower limb amputation in the diabetic and non-diabetic population of England 2003-2013. - Diabetes & vascular disease research
To determine the prevalence of amputation and revascularisation among diabetics and non-diabetics between 2003 and 2013.Retrospective analysis of English hospital data with census estimates for population aged 50-84 years.There were 42,294 major and 52,525 minor amputations and 355,545 revascularisations. Major amputation rates fell by 20% (27.7-22.9), with minor amputations (22.9-35.2) and revascularisations (199.8-245.4) rising. The major amputation rate reduced in diabetics (men, 180.5-111.8; women, 92.8-52.7) faster than non-diabetics (men, 24.6-18.7; women, 11.0-8.9). In total, 48.2% of men and 58.0% of women amputees were not diabetic.Diabetics continue to experience six times the rate of amputation than non-diabetics. However, half of major amputees were not diabetic and experienced slower rates of decrease. Non-diabetics, particularly those with peripheral arterial disease, should have access to appropriate services, particularly foot care.© The Author(s) 2016.
A neoflavonoid dalsissooal isolated from heartwood of Dalbergia sissoo Roxb. has bone forming effects in mice model for osteoporosis. - European journal of pharmacology
Dalbergia sissoo Roxb. is a well known medicinal plant of India, enriched with various flavonoids used for treating multiple diseases. Earlier, we have shown that extract of Dalbergia sissoo Roxb. leaves mitigate ovariectomy induced bone loss and pure compounds (neoflavonoids) isolated from it, promote osteoblastogenesis in primary calvarial osteoblasts cells in vitro. Here, we hypothesize that dalsissooal (DSL), a novel neoflavonoid isolated from the heartwood of Dalbergia sissoo Roxb. is an important constituent of the extract that imparts bone forming effects. Treatment with DSL enhanced trabecular bone micro-architecture parameters, biomechanical strength, increased bone formation rate and mineral apposition rate in OVx mice comparable to 17β-estradiol. It increased bone formation by enhancing osteoblast gene expression and reduced bone turnover by decreasing osteoclastic gene expressions. Interestingly, we observed that DSL has no uterine estrogenic effects. At cellular levels, DSL promoted differentiation of bone marrow cells as well as calvaria osteoblast cells towards osteoblast lineage by enhancing differentiation and mineralizing ability to form mineralizing nodules via stimulating BMP-2 and RunX-2 expressions. Overall, our data suggest that oral supplementation of a novel neoflavonoid dalsissooal isolated from heartwood of Dalbergia sissoo Roxb. exhibited bone anabolic action by improving structural property of bone, promoting new bone formation and reducing bone turnover rate in post-menopausal model for osteoporosis with no uterine hyperplasia.Copyright © 2016 Elsevier B.V. All rights reserved.
Genetically engineered flavonol enriched tomato fruit modulates chondrogenesis to increase bone length in growing animals. - Scientific reports
Externally visible body and longitudinal bone growth is a result of proliferation of chondrocytes. In growth disorder, there is delay in the age associated increase in height. The present study evaluates the effect of extract from transgenic tomato fruit expressing AtMYB12 transcription factor on bone health including longitudinal growth. Constitutive expression of AtMYB12 in tomato led to a significantly enhanced biosynthesis of flavonoids in general and the flavonol biosynthesis in particular. Pre-pubertal ovary intact BALB/c mice received daily oral administration of vehicle and ethanolic extract of wild type (WT-TOM) and transgenic AtMYB12-tomato (MYB12-TOM) fruits for six weeks. Animal fed with MYB12-TOM showed no inflammation in hepatic tissues and normal sinusoidal Kupffer cell morphology. MYB12-TOM extract significantly increased tibial and femoral growth and subsequently improved the bone length as compared to vehicle and WT-TOM. Histomorphometry exhibited significantly wider distal femoral and proximal tibial growth plate, increased number and size of hypertrophic chondrocytes in MYB12-TOM which corroborated with micro-CT and expression of BMP-2 and COL-10, marker genes for hypertrophic cells. We conclude that metabolic reprogramming of tomato by AtMYB12 has the potential to improve longitudinal bone growth thus helping in achievement of greater peak bone mass during adolescence.
MicroRNA 874-3p Exerts Skeletal Anabolic Effects Epigenetically during Weaning by Suppressing Hdac1 Expression. - The Journal of biological chemistry
Embryonic skeletogenesis and postnatal bone development require the transfer of calcium from the mother to the offspring during pregnancy and lactation. Therefore, bone resorption in the mother becomes elevated during these periods, resulting in significant maternal skeletal loss. There follows an anabolic phase around weaning during which there is a remarkable recovery of the maternal skeleton. However, the mechanism(s) of this anabolic response remain(s) largely unknown. We identified eight differentially expressed miRNAs by array profiling, of which miR-874-3p was highly expressed at weaning, a time when bone loss was noted to recover. We report that this weaning-associated miRNA is an anabolic target. Therefore, an agomir of miR-874-3p induced osteoblast differentiation and mineralization. These actions were mediated through the inhibition of Hdac1 expression and enhanced Runx2 transcriptional activation. When injected in vivo, the agomir significantly increased osteoblastogenesis and mineralization, reversed bone loss caused by ovariectomy, and increased bone strength. We speculate that elevated miR-874-3p expression during weaning enhances bone formation and that this miRNA may become a therapeutic target for conditions of bone loss.© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.
Awareness of treatment needs and length of stay amongst psychiatric inpatients. - Comprehensive psychiatry
Inpatient psychiatric units experience significant pressure from third party payers to keep length of stay (LOS) to a minimum despite having to treat more severely ill patients. However, there is a paucity of empiric data for guiding treatment decisions that maximize therapeutic outcome while minimizing LOS. We therefore endeavored to begin utilizing a newly created psychometric instrument that assesses patient psychological factors, which we propose will allow for LOS prediction and individualization of therapeutic outcome.The Goals Questionnaire (GQ), created to determine awareness of treatment needs, was administered to newly admitted patients. Linear regression analyses were conducted to ascertain the relationship between the GQ score and LOS, as well as the effects of confounding factors.A significant and inverse relationship was found between the GQ score and LOS (β=-4.4; p=0.007) that was dependent upon (i.e., had a significant interaction with) age and substance use disorders. There was minimal confounding from common administrative, legal, and clinical factors.The GQ may have utility for inpatient treatment teams, providing information that can be used to maximize and individualize therapeutic outcome while minimizing LOS.Copyright © 2015 Elsevier Inc. All rights reserved.
Endovascular revascularization is associated with a lower risk of above knee amputation than surgical or combined modalities. Analysis of English hospital admissions over a six year period. - International angiology : a journal of the International Union of Angiology
We aimed to determine whether revascularization modality affected risk of an above knee amputation (AKA) in patients with peripheral arterial disease.We used English hospital data and began by determining the number of major amputations and revascularization procedures performed between 1st April 2003- 31st March 2009. We then extracted demographic (age, sex, level of deprivation, treatment location), comorbidity (diabetes, hypertension, hypercholesterolemia, coronary heart disease, ischemic cerebrovascular disease and smoking) and revascularization modality (endovascular/surgical) data. Multi-variate analysis determined the odds ratios of an AKA in relation to previous revascularization attempts (if any).Over the six year period, there were 25,312 major amputations of which 7544 (29.4%) were linked to a revascularization attempt. Level of amputation was significantly influenced by previous revascularization. Compared to patients not linked to revascularization, those requiring endovascular treatment were less likely to undergo an AKA (OR 0.82; 95% CI 0.75-0.90). Surgical (OR 1.16; 1.07-1.25) and combined endovascular/surgical treatment (OR 1.24; 1.09-1.40) had the opposite effect. Men (0.64; 0.55-0.74) and diabetics (0.44; 0.55-0.74) were less likely to undergo an AKA whereas patients with coronary (1.28; 1.10-1.47) or cerebrovascular (1.90; 1.33-2.71) disease were more likely to have the procedure. Age, deprivation, hypertension, hypercholesterolemia, smoking and geographical location did not influence the level of amputation.When a major leg amputation is necessary, the risk of this being carried out above the knee may be lowest after endovascular revascularization attempts and highest after combined endovascular and surgical treatment.
Nanotechnology -New Lifeline For Food Industry. - Critical reviews in food science and nutrition
Nanotechnology is an enable technology that has the potential to revolutionize agriculture and food systems. Food nanotechnology is an area of emerging interest and opens up a whole universe of new possibilities for the food industry. The basic categories of nanotechnology applications and functionalities currently in the development of food packaging include: the improvement of plastic materials barriers, the incorporation of active components that can deliver functional attributes beyond those of conventional active packaging, and the sensing and signaling of relevant information. Nano food packaging materials may extend food life, improve food safety, alert consumers that food is contaminated or spoiled, repair tears in packaging, and even release preservatives to extend the life of the food in the package. Nanotechnology applications in the food industry can be utilized to detect bacteria in packaging, or produce stronger flavors and color quality, and safety by increasing the barrier properties. Nanotechnology holds great promise to provide benefits not just within food products but also around food products. In fact, nanotechnology introduces new chances for innovation in the food industry at immense speed, but uncertainty and health concerns are also emerging.
Preventive effects of withaferin A isolated from the leaves of an Indian medicinal plant Withania somnifera (L.): comparisons with 17-β-estradiol and alendronate. - Nutrition (Burbank, Los Angeles County, Calif.)
Bone protective effects of withaferin A (WFA) from leaves of Withania somnifera (L.) were evaluated in preventive model of Balb/c mice with 17 β-estradiol (E2) and alendronate (ALD).Adult female Balb/c mice, 7 to 9 wk, were bilaterally ovariectomized (OVx) to mimic the state of E2 deficiency. Immediately after surgery mice were administrated WFA at doses of 1, 5, 10 mg/kg/d while other two OVx groups received ALD or E2 for 2 mo. Sham and OVx groups with vehicle and no treatment served as controls.WFA administration increased new bone formation, as well as improving microarchitecture and biomechanical strength of the bones. It prevented bone loss by reducing expression of osteoclastic genes tartrate resistant acid phosphatase (TRAP) and receptor activator of nuclear factor κ B (RANK). Increase in bone turnover marker, osteocalcin (OCN) and inflammatory cytokine tumor necrosis factor-alpha (TNF-α) because of ovariectomy were reduced with WFA treatment, with effects comparable to E2 administration. Histomorphometric analysis of uterus shows that WFA was not fraught with estrogenic or antiestrogenic effects. At cellular level, WFA promoted differentiation of bone marrow cells (BMCs) and increased mineralization by inducing expression of osteogenic genes. WFA has bone protective potential as its treatment prevents bone loss that is comparable to ALD and E2.It is surmised that WFA in preclinical setting is effective in preserving bone loss by both inhibition of resorption and stimulation of new bone formation before onset of osteoporosis with no uterine hyperplasia.Copyright © 2015 Elsevier Inc. All rights reserved.
Lower limb amputation in England: prevalence, regional variation and relationship with revascularisation, deprivation and risk factors. A retrospective review of hospital data. - Journal of the Royal Society of Medicine
We describe the prevalence of major lower limb amputation across England and its relationship with revascularisation, patient demography and disease risk factors.Retrospective cohort study.England 1 April 2003 to 31 March 2009.Patients aged 50-84 years.Age standardised prevalence rates were calculated using Hospital Episode Statistics as the numerator with census data as the denominator. The outcome measure 'amputation with revascularisation' was created if an amputation could be linked with a revascularisation. Logistic regression determined the odds of having an amputation with a revascularisation across England. Regression was performed unadjusted and repeated after controlling for demographic (age, sex, social deprivation) and disease risk factors (diabetes, hypertension, coronary heart disease, cerebrovascular disease, smoking).There were 25,312 amputations and 136,215 revascularisations, and 7543 cases were linked. The prevalence rate per 100,000 (95% confidence intervals) for amputation was 26.3 (26.0-26.6) with rates significantly higher in Northern England (North: 31.7; 31.0-32.3, Midlands: 26.0; 25.3-26.7, South: 23.1; 22.6-23.5). The revascularisation rate was 141.6 (140.8-142.3) with significantly higher rates again in Northern England (North: 182.1; 180.5-183.7, Midlands: 121.3; 119.8-122.9, South 124.9; 123.9-125.8). The odds of having an amputation with a revascularisation remained significantly higher in the North (OR 1.22; 1.13-1.33) even after controlling demographic and disease risk factors.There is a North-South divide in England for both major lower limb amputation and revascularisation. The higher odds of having an amputation with a revascularisation in the North were not fully explained by greater levels of deprivation or disease risk factors.© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Map & Directions

14120 Ne 183Rd St Unit 333 Woodinville, WA 98072
View Directions In Google Maps

Nearby Doctors

17311 135Th Ave Ne A-700
Woodinville, WA 98072
425 884-4944
17000 140Th Ave Ne #102
Woodinville, WA 98072
425 835-5437
Woodinville Towne Center 17638 140Th Ave Ne
Woodinville, WA 98072
425 854-4100
17630 140Th Ave Ne Ste A
Woodinville, WA 98072
425 983-3900
12533 Ne 160Th Pl
Woodinville, WA 98072
206 528-8351
24008 Snohomish Woodinville Rd
Woodinville, WA 98072
425 067-7704
18500 156Th Ave Ne Ste 202
Woodinville, WA 98072
425 815-5700
17000 140Th Ave Ne Suite 101
Woodinville, WA 98072
425 816-6363
16316 173Rd Ave Ne
Woodinville, WA 98072
425 184-4760
18500 156Th Ave Ne Ste 202
Woodinville, WA 98072
206 372-2026